An open‐label study on ulotaront's effects on insulin‐glucose regulation in schizophrenia patients with metabolic syndrome and prediabetes: Part I
Authors' conclusion
Despite limited sample size, primary endpoints favoured ulotaront over prior antipsychotics with respect to a reduction trend in glucose, c-peptide and insulin. The insulin response after a solid meal was nominally significant, suggesting that semi-chronic twice-a-day dosing of ulotaront might improve insulin dynamics in schizophrenia patients at high diabetes risk.
Study context
- Population
- Schizophrenia patients with metabolic syndrome and prediabetes
- Comparison
- Ulotaront twice daily vs baseline on prior antipsychotic treatment
- Outcome
- Glucose, c-peptide and insulin (primary endpoints), ulotaront vs prior antipsychotics
Methodological detailsmulti-dose, comparison with each participant's baseline on prior antipsychotic
- Multi-dose
- Comparison with each participant's baseline on prior antipsychotic
Main finding
As reported in the abstract
Mean change from baseline in AUCs (OGTT and MMTT) · up to 3 weeks
- OGTT glucose AUC, mean change from baseline
- −19.7 h × mg/dL
- OGTT C-peptide AUC, mean change from baseline
- −269 h × pg/mL
- OGTT insulin AUC, mean change from baseline
- −41.0 h × uIU/mL
- Mixed meal tolerance test (MMTT) glucose AUC, mean change from baseline
- −10.8 h × mg/dL
- MMTT C-peptide AUC, mean change from baseline
- −2860 h × pg/mL
- MMTT insulin AUC, mean change from baseline
- −132 h × mg/dL
- Insulin response during MMTT reached nominal statistical significance
- p = 0.021, effect size = −0.7
Further findings
Gastric emptying time (GEBT)
- Mean change from baseline gastric emptying time
- −0.60 min
Original publication
An open‐label study on ulotaront's effects on insulin‐glucose regulation in schizophrenia patients with metabolic syndrome and prediabetes: Part I. Diabetes Obes Metab. Published 22 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →